Susan Boyd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Susan Boyd has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Michael John Milloy
British Columbia Centre on Substance Use
3 shared publications - Philippe Lucas
Michigan Psychedelic Center, University of Michigan, Ann Arbor, MI, USA
3 shared publications - Zach Walsh
Department of Psychology, University of British Columbia, Kelowna, Canada
3 shared publications - Barbara M. Moffat
School of Nursing, University of British Columbia, 302-6190 Agronomy Road, Vancouver, BC V6T 1Z3, Canada.
2 shared publications - Joy Louise Johnson
University of British Columbia
2 shared publications - Andrew Ivsins
British Columbia Centre on Substance Use, Vancouver, BC, Canada; Department of Medicine, University of British Columbia, Vancouver, BC, Canada
1 shared publication
Latest Publications
- Open Access
- 28 July 2021
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 3 (1) , 1-14
The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients
Background: Despite repeated calls by medical associations to gather evidence on the harms and benefits of cannabis, there are ongoing methodological challenges to conducting observational and clinical studies on cannabis, including a high rate of patients that are lost to follow-up (LTFU). This study explores factors potentially associated with retention in a large prospective study of Canadian medical cannabis patients, with the goal of reducing the probability that patients will be lost to follow-up in future cannabis research.Methods: The Tilray Observational Patient Study (TOPS) was a multi-site, prospective study assessing the impact of medical cannabis over 6 months in a broad population of authorized Canadian cannabis patients. The study took place from 2016 to 19, and we conducted a series of exploratory analyses including a Kaplan–Meier survival analysis and logistic regressions to assess the potential association between study retention and variables including patient characteristics, cannabis and prescription drug use, quality of life, and the legalization of non-medical cannabis.Results: Overall, 1011 participants were included in this analysis, contributing 287 patient-years of data. Retention was 728 (72%) at 3 months, and 419 (41.4%) at 6 months. Our analyses found significantly lower adjusted odds of retention following legalization (AOR 0.28, 95% CI 0.18–0.41), and in patients that used prescription opioids at baseline (AOR 0.62, 95% CI 0.46–0.85), while increased odds of retention were found in patients with a higher baseline psychological score (AOR 1.43, 95% CI 1.08–1.90) or that used anti-seizure medications at baseline (AOR 1.91, 95% CI 1.30–2.81).Discussion: TOPS provided a unique opportunity to examine patient characteristics and other variables that may be associated with retention in prospective medical cannabis studies. Our findings highlight some of the challenges of conducting medical cannabis research at a time when patients have a multitude of cannabis access options, including legal adult dispensaries and a robust illicit market. High LTFU rates can impact the validity of studies, and potentially lead to misestimations of the harms and benefits of medical cannabis use. Despite being a multi-site prospective study, this was a convenience sample, thereby limiting the generalizability of these findings. Additionally, data regarding the use of cannabis was self-reported by patients, so is subject to potential recall bias.Conclusion: We found evidence that external policy changes that affect access to cannabis such as the legalization of non-medical adult use and patient characteristics associated with patient physical/psychological capacity can impact retention in prospective medical cannabis studies. Evidence-based strategies to reduce study burden on participants, such as minimizing in-person visits by providing digitized internet-based surveys and phone or telemedicine follow-up options as well as ensuring adequate participant compensation could improve retention. Additionally, policy-related changes aimed at improving access to medical cannabis, including increased cost-coverage and community-based distribution, could encourage patients to remain in the federal medical cannabis program and thereby reduce LTFU in associated studies.
- 28 July 2021
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 3 (1) , 1-14
Open AccessThe impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients
Background: Despite repeated calls by medical associations to gather evidence on the harms and benefits of cannabis, there are ongoing methodological challenges to conducting observational and clinical studies on cannabis, including a high rate of patients that are lost to follow-up (LTFU). This study explores factors potentially associated with retention in a large prospective study of Canadian medical cannabis patients, with the goal of reducing the probability that patients will be lost to follow-up in future cannabis research.Methods: The Tilray Observational Patient Study (TOPS) was a multi-site, prospective study assessing the impact of medical cannabis over 6 months in a broad population of authorized Canadian cannabis patients. The study took place from 2016 to 19, and we conducted a series of exploratory analyses including a Kaplan–Meier survival analysis and logistic regressions to assess the potential association between study retention and variables including patient characteristics, cannabis and prescription drug use, quality of life, and the legalization of non-medical cannabis.Results: Overall, 1011 participants were included in this analysis, contributing 287 patient-years of data. Retention was 728 (72%) at 3 months, and 419 (41.4%) at 6 months. Our analyses found significantly lower adjusted odds of retention following legalization (AOR 0.28, 95% CI 0.18–0.41), and in patients that used prescription opioids at baseline (AOR 0.62, 95% CI 0.46–0.85), while increased odds of retention were found in patients with a higher baseline psychological score (AOR 1.43, 95% CI 1.08–1.90) or that used anti-seizure medications at baseline (AOR 1.91, 95% CI 1.30–2.81).Discussion: TOPS provided a unique opportunity to examine patient characteristics and other variables that may be associated with retention in prospective medical cannabis studies. Our findings highlight some of the challenges of conducting medical cannabis research at a time when patients have a multitude of cannabis access options, including legal adult dispensaries and a robust illicit market. High LTFU rates can impact the validity of studies, and potentially lead to misestimations of the harms and benefits of medical cannabis use. Despite being a multi-site prospective study, this was a convenience sample, thereby limiting the generalizability of these findings. Additionally, data regarding the use of cannabis was self-reported by patients, so is subject to potential recall bias.Conclusion: We found evidence that external policy changes that affect access to cannabis such as the legalization of non-medical adult use and patient characteristics associated with patient physical/psychological capacity can impact retention in prospective medical cannabis studies. Evidence-based strategies to reduce study burden on participants, such as minimizing in-person visits by providing digitized internet-based surveys and phone or telemedicine follow-up options as well as ensuring adequate participant compensation could improve retention. Additionally, policy-related changes aimed at improving access to medical cannabis, including increased cost-coverage and community-based distribution, could encourage patients to remain in the federal medical cannabis program and thereby reduce LTFU in associated studies.
- 1 May 2021
- Published by Elsevier in International Journal of Drug Policy
- Vol. 91, 102938
Heroin and the illegal drug overdose death epidemic: A history of missed opportunities and resistance
- 1 May 2021
- Published by Elsevier in International Journal of Drug Policy
- Vol. 91, 102938
Heroin and the illegal drug overdose death epidemic: A history of missed opportunities and resistance
- 1 December 2020
- Published by Elsevier in International Journal of Drug Policy
- Vol. 86, 102963
Reductions in alcohol use following medical cannabis initiation: results from a large cross-sectional survey of medical cannabis patients in Canada
- 1 December 2020
- Published by Elsevier in International Journal of Drug Policy
- Vol. 86, 102963
Reductions in alcohol use following medical cannabis initiation: results from a large cross-sectional survey of medical cannabis patients in Canada
- 1 April 2020
- Published by Elsevier in International Journal of Drug Policy
- Vol. 78, 102690
Problematizing the DSM-5 criteria for opioid use disorder: A qualitative analysis
- 1 April 2020
- Published by Elsevier in International Journal of Drug Policy
- Vol. 78, 102690
Problematizing the DSM-5 criteria for opioid use disorder: A qualitative analysis
- 1 June 2019
- Published by Elsevier in International Journal of Drug Policy
- Vol. 68, 109-116
Gendered drug policy: Motherisk and the regulation of mothering in Canada
- 1 June 2019
- Published by Elsevier in International Journal of Drug Policy
- Vol. 68, 109-116
Gendered drug policy: Motherisk and the regulation of mothering in Canada
- Open Access
- 3 July 2017
- Published by Taylor & Francis in Contemporary Justice Review
- Vol. 20 (3) , 297-298
A call to action: women and the drug war
(2017). A call to action: women and the drug war. Contemporary Justice Review: Vol. 20, No. 3, pp. 297-298.
- 3 July 2017
- Published by Taylor & Francis in Contemporary Justice Review
- Vol. 20 (3) , 297-298
Open AccessA call to action: women and the drug war
(2017). A call to action: women and the drug war. Contemporary Justice Review: Vol. 20, No. 3, pp. 297-298.
- Open Access
- 18 May 2017
- Published by Springer Nature in Harm Reduction Journal
- Vol. 14 (1) , 1-14
Telling our stories: heroin-assisted treatment and SNAP activism in the Downtown Eastside of Vancouver
This article highlights the experiences of a peer-run group, SALOME/NAOMI Association of Patients (SNAP), that meets weekly in the Downtown Eastside of Vancouver, British Columbia, Canada. SNAP is a unique independent peer- run drug user group that formed in 2011 following Canada’s first heroin-assisted treatment trial (HAT), North America Opiate Medication Initiative (NAOMI). SNAP’s members are now made up of former research participants who participated in two heroin-assisted trials in Vancouver. This article highlights SNAP members’ experiences as research subjects in Canada’s second clinical trial conducted in Vancouver, Study to Assess Longer-term Opioid Medication Effectiveness (SALOME), that began recruitment of research participants in 2011. This paper draws on one brainstorming session, three focus groups, and field notes, with the SALOME/NAOMI Association of Patients (SNAP) in late 2013 about their experiences as research subjects in Canada’s second clinical trial, SALOME in the DTES of Vancouver, and fieldwork from a 6-year period (March 2011 to February 2017) with SNAP members. SNAP’s research draws on research principles developed by drug user groups and critical methodological frameworks on community-based research for social justice. The results illuminate how participating in the SALOME clinical trial impacted the lives of SNAP members. In addition, the findings reveal how SNAP member’s advocacy for HAT impacts the group in positive ways. Seven major themes emerged from the analysis of the brainstorming and focus groups: life prior to SALOME, the clinic setting and routine, stability, 6-month transition, support, exiting the trial and ethics, and collective action, including their participation in a constitutional challenge in the Supreme Court of BC to continue receiving HAT once the SALOME trial ended. HAT benefits SNAP members. They argue that permanent HAT programs should be established in Canada because they are an effective harm reduction initiative, one that also reduces opioid overdose deaths.
- 18 May 2017
- Published by Springer Nature in Harm Reduction Journal
- Vol. 14 (1) , 1-14
Open AccessTelling our stories: heroin-assisted treatment and SNAP activism in the Downtown Eastside of Vancouver
This article highlights the experiences of a peer-run group, SALOME/NAOMI Association of Patients (SNAP), that meets weekly in the Downtown Eastside of Vancouver, British Columbia, Canada. SNAP is a unique independent peer- run drug user group that formed in 2011 following Canada’s first heroin-assisted treatment trial (HAT), North America Opiate Medication Initiative (NAOMI). SNAP’s members are now made up of former research participants who participated in two heroin-assisted trials in Vancouver. This article highlights SNAP members’ experiences as research subjects in Canada’s second clinical trial conducted in Vancouver, Study to Assess Longer-term Opioid Medication Effectiveness (SALOME), that began recruitment of research participants in 2011. This paper draws on one brainstorming session, three focus groups, and field notes, with the SALOME/NAOMI Association of Patients (SNAP) in late 2013 about their experiences as research subjects in Canada’s second clinical trial, SALOME in the DTES of Vancouver, and fieldwork from a 6-year period (March 2011 to February 2017) with SNAP members. SNAP’s research draws on research principles developed by drug user groups and critical methodological frameworks on community-based research for social justice. The results illuminate how participating in the SALOME clinical trial impacted the lives of SNAP members. In addition, the findings reveal how SNAP member’s advocacy for HAT impacts the group in positive ways. Seven major themes emerged from the analysis of the brainstorming and focus groups: life prior to SALOME, the clinic setting and routine, stability, 6-month transition, support, exiting the trial and ethics, and collective action, including their participation in a constitutional challenge in the Supreme Court of BC to continue receiving HAT once the SALOME trial ended. HAT benefits SNAP members. They argue that permanent HAT programs should be established in Canada because they are an effective harm reduction initiative, one that also reduces opioid overdose deaths.
- 1 July 2015
- Published by Elsevier in International Journal of Drug Policy
- Vol. 26 (7) , 636-644
Visual and narrative representations of mental health and addiction by law enforcement
- 1 July 2015
- Published by Elsevier in International Journal of Drug Policy
- Vol. 26 (7) , 636-644
Visual and narrative representations of mental health and addiction by law enforcement
- 1 June 2014
- Published by SAGE Publications in Contemporary Drug Problems
- Vol. 41 (2) , 201-232
The Criminal Addict: Canadian Radio Documentary Discourse, 1957–1969
This article examines early Canadian Broadcasting Corporation radio documentaries on drugs and addiction from 1957 to 1969. Socio-historical and discourse analyses were applied to radio documentaries in this study. This article highlights how discourse about “criminal addicts” is related to conceptions of drugs, addiction, criminality, drug treatment, people who use criminalized drugs, and the professionals who regulate them. In this article, I argue that the lack of public drug treatment in Canada during this period is related to the social concept of the addict as a criminal first and a person addicted second. In addition, the diverse voices of people who used criminalized drugs such as heroin — that is, those most affected by drug prohibition and criminal addict discourse — were a clear thread of resistance throughout the study sample. In conclusion, I discuss briefly how the notion of the criminal addict has endured in Canada.
- 1 June 2014
- Published by SAGE Publications in Contemporary Drug Problems
- Vol. 41 (2) , 201-232
The Criminal Addict: Canadian Radio Documentary Discourse, 1957–1969
This article examines early Canadian Broadcasting Corporation radio documentaries on drugs and addiction from 1957 to 1969. Socio-historical and discourse analyses were applied to radio documentaries in this study. This article highlights how discourse about “criminal addicts” is related to conceptions of drugs, addiction, criminality, drug treatment, people who use criminalized drugs, and the professionals who regulate them. In this article, I argue that the lack of public drug treatment in Canada during this period is related to the social concept of the addict as a criminal first and a person addicted second. In addition, the diverse voices of people who used criminalized drugs such as heroin — that is, those most affected by drug prohibition and criminal addict discourse — were a clear thread of resistance throughout the study sample. In conclusion, I discuss briefly how the notion of the criminal addict has endured in Canada.